New study uncovers mechanisms of bacterial dormancy involving protein aggregation

Researchers revealed a mechanism involving protein aggregation that allows bacteria to enter a dormant state

Leuven, 28 January 2025 – Researchers at the VIB-KU Leuven Center for Microbiology and the VIB-KU Leuven Center for Brain & Disease Research revealed a mechanism involving protein aggregation that allows bacteria to enter a dormant state, a phenomenon that is associated with the persistence of infections and the challenge of antibiotic resistance. Their work appears in Nature Communications.

Sleeping bacteria

As antibiotic resistance continues to escalate globally, understanding how bacteria can evade treatment is more critical than ever. Some bacteria can enter dormant states, during which they are not susceptible to antibiotics. Dormant bacteria, including persister cells and viable but non-culturable cells (VBNCs), survive antibiotic exposure and can later ‘reactivate’, leading to recurrent infections. One of the bacteria that can pull off this trick is Escherichia coli, commonly associated with various infections in humans.

Led by Prof. Jan Michiels (VIB-KU Leuven) and Prof. Liselot Dewachter (UCLouvain), the researchers, alongside colleagues from the Switch lab (VIB-KU Leuven), explored the relationship between protein aggregation and bacterial dormancy.

“We found,” says Prof. Dewachter, “that when we subject bacteria to stress, proteins involved in their energy metabolism start to condensate, meaning that they start to clump together in gel-like droplets. Over time, these droplets solidify, which may protect the bacteria and help them survive. Interestingly, while protein aggregation has previously been associated with neurodegenerative diseases like Alzheimer’s, our findings reveal a surprising positive side to protein aggregation. Our work shows that protein aggregates are not necessarily detrimental, but can actually benefit cells by promoting their survival in stressful environments, such as during antibiotic treatment.”

Different states

The authors show that the two processes – bacterial dormancy and protein condensation – are tightly connected. By aggregating several proteins involved in metabolism, the condensation process effectively shuts down bacterial energy production.

Dr. Celien Bollen, first author of the study, explains, “We found that the timing of protein condensation and dormancy is closely linked across different strains of E. coli. This suggests that the process is conserved, potentially offering a therapeutic target for future treatments.”

Importantly, the scientists found that dormant E. coli cells can recover and regrow by dissolving these protein aggregates. The chaperone protein DnaK can literally pull proteins out of the condensates and reactivate bacterial metabolism.

“There are different states of dormancy,” explains Prof. Jan Michiels. “The bacteria first enter a persister state, where metabolism slows down and energy-related proteins start to form condensates, but they still show some activity, akin to a sleeping state. However, if the stress lasts, the protein droplets solidify and the bacteria transition into the VBNC state. In this state, metabolism drops even further, and it takes the bacteria longer to become active again, resembling more of a coma.”
“By disrupting the processes that lead to dormancy,” Bollen adds, “we may be able to improve the effectiveness of existing antibiotics and reduce the incidence of persistent infections. This is particularly relevant in the context of rising antibiotic resistance, which is a significant threat to public health.”
Celien Bollen and Jan Michiels

Publication

Composition and liquid-to-solid maturation of protein aggregates contribute to bacterial dormancy development and recovery. Bollen et al, Nature Communications, 2025.

Funding

This work was supported by FWO, KU Leuven, and VIB.


Gunnar De Winter

Gunnar De Winter

Science Communications Expert, VIB

 

 

Share

Latest stories

Website preview
New research brings personalized treatment for Parkinson’s disease a step closer
Leuven, 5 May 2026 – A new study led by researchers from VIB and KU Leuven shows that Parkinson’s disease can be divided into distinct subtypes, helping explain why a single treatment does not work for all patients. Using an machine-learning-driven analysis, the team identified two main groups and five subgroups of the disease, marking an important step toward more personalized therapies. The findings were recently published in Nature Communications.
press.vib.be
Website preview
New lung cancer model reveals how tumor location shapes the immune response
Brussels, 27 April 2026 – Researchers at VIB and VUB have developed a powerful new way to study how the immune system behaves inside lung tumors. By combining a patient-relevant mouse model with single-cell technologies, the team provides one of the most comprehensive immune maps to date of lung adenocarcinoma, which is the most common subtype of lung cancer. Their work appears in Nature Communications.
press.vib.be
Website preview
Molecular keyhole sheds light on pain and epilepsy
Leuven, 21 April 2026 – Researchers at VIB, VUB, and KU Leuven have identified a tiny binding site, a molecular ’keyhole’, in the TRPM3 ion channel, a crucial sensor in pain signaling. TRPM3 is also linked to rare neurodevelopmental disorders and epilepsy. In a recent study published in Nature Communications, the researchers found that even the slightest change in this keyhole can radically switch the channel’s behavior, explaining how certain mutations can flip the effects of drugs.
press.vib.be

About VIB Press

VIB is an independent research institute that translates insights in biology into impactful innovations for society. Collaborating with the five Flemish universities, it conducts research in plant biology, cancer, neuroscience, microbiology, inflammatory diseases, artificial intelligence and more. VIB connects science with entrepreneurship and stimulates the growth of the Flemish biotech ecosystem. The institute contributes to solutions for societal challenges such as new methods for diagnostics and treatments, as well as innovations for agriculture. 

Learn more at www.vib.be.

Contact

Suzanne Tassierstraat 1 9052 Zwijnaarde

+32 9 244 66 11

press@vib.be

vib.be